Suppr超能文献

AMP激活的蛋白激酶作为一种药物靶点。

AMP-activated protein kinase as a drug target.

作者信息

Hardie D Grahame

机构信息

Division of Molecular Physiology, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom.

出版信息

Annu Rev Pharmacol Toxicol. 2007;47:185-210. doi: 10.1146/annurev.pharmtox.47.120505.105304.

Abstract

The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.

摘要

AMP激活的蛋白激酶(AMPK)系统是细胞和全身水平能量平衡的调节因子,一旦被低能量状态激活,它会促使从消耗ATP的合成代谢途径转变为产生ATP的分解代谢途径。现在它似乎是用于治疗2型糖尿病的两类现有药物(即双胍类和噻唑烷二酮类)的主要靶点。然而,在这两种情况下,这些药物都是间接激活AMPK,一个有趣的问题是,直接激活AMPK的药物是否能在消除不良副作用的同时保留现有药物的治疗益处。AMPK激活剂现在也有作为抗癌药物的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验